vs
Protalix BioTherapeutics, Inc.（PLX）与Red Cat Holdings, Inc.（RCAT）财务数据对比。点击上方公司名可切换其他公司
Red Cat Holdings, Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.1倍（$9.6M vs $9.1M），Protalix BioTherapeutics, Inc.净利率更高（-60.3% vs -166.0%，领先105.7%），Red Cat Holdings, Inc.同比增速更快（988.2% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-24.5M）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
Mega Cat Studios是一家总部位于美国宾夕法尼亚州匹兹堡的电子游戏开发与发行企业，由詹姆斯·迪根、尼克·曼恩和扎克·曼科于2015年共同创立，专注于游戏内容的研发与全球发行布局。
PLX vs RCAT — 直观对比
营收规模更大
RCAT
是对方的1.1倍
$9.1M
营收增速更快
RCAT
高出1038.1%
-49.9%
净利率更高
PLX
高出105.7%
-166.0%
自由现金流更多
PLX
多$26.1M
$-24.5M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $9.6M |
| 净利润 | $-5.5M | $-16.0M |
| 毛利率 | 49.4% | 6.6% |
| 营业利润率 | -51.1% | -181.7% |
| 净利率 | -60.3% | -166.0% |
| 营收同比 | -49.9% | 988.2% |
| 净利润同比 | -184.8% | -29.0% |
| 每股收益（稀释后） | $-0.06 | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXRCAT
| Q4 25 | $9.1M | — | ||
| Q3 25 | $17.9M | $9.6M | ||
| Q2 25 | $15.7M | — | ||
| Q1 25 | $10.1M | $1.6M | ||
| Q4 24 | $18.2M | $0 | ||
| Q3 24 | $18.0M | — | ||
| Q2 24 | $13.5M | — | ||
| Q1 24 | — | $5.8M |
净利润PLXRCAT
| Q4 25 | $-5.5M | — | ||
| Q3 25 | $2.4M | $-16.0M | ||
| Q2 25 | $164.0K | — | ||
| Q1 25 | $-3.6M | $-23.1M | ||
| Q4 24 | $6.5M | $-13.3M | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $-2.2M | — | ||
| Q1 24 | — | $-5.5M |
毛利率PLXRCAT
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | 6.6% | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | -52.2% | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | 18.8% |
营业利润率PLXRCAT
| Q4 25 | -51.1% | — | ||
| Q3 25 | 11.9% | -181.7% | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | -41.0% | -765.7% | ||
| Q4 24 | 39.6% | — | ||
| Q3 24 | 22.2% | — | ||
| Q2 24 | -18.0% | — | ||
| Q1 24 | — | -76.0% |
净利率PLXRCAT
| Q4 25 | -60.3% | — | ||
| Q3 25 | 13.2% | -166.0% | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | -35.8% | -1418.9% | ||
| Q4 24 | 35.6% | — | ||
| Q3 24 | 18.0% | — | ||
| Q2 24 | -16.4% | — | ||
| Q1 24 | — | -93.9% |
每股收益（稀释后）PLXRCAT
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.03 | $-0.16 | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $-0.05 | $-0.27 | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.03 | — | ||
| Q2 24 | $-0.03 | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $253.3M |
| 总资产 | $82.3M | $286.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLXRCAT
| Q4 25 | $14.7M | — | ||
| Q3 25 | $13.6M | — | ||
| Q2 25 | $17.9M | — | ||
| Q1 25 | $19.5M | — | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.4M | — | ||
| Q2 24 | $23.4M | — | ||
| Q1 24 | — | — |
股东权益PLXRCAT
| Q4 25 | $48.2M | — | ||
| Q3 25 | $52.9M | $253.3M | ||
| Q2 25 | $49.9M | — | ||
| Q1 25 | $45.2M | $28.9M | ||
| Q4 24 | $43.2M | $27.0M | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $28.6M | — | ||
| Q1 24 | — | $49.6M |
总资产PLXRCAT
| Q4 25 | $82.3M | — | ||
| Q3 25 | $82.3M | $286.0M | ||
| Q2 25 | $78.5M | — | ||
| Q1 25 | $73.9M | $59.7M | ||
| Q4 24 | $73.4M | $51.1M | ||
| Q3 24 | $61.6M | — | ||
| Q2 24 | $91.5M | — | ||
| Q1 24 | — | $55.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $-23.9M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $-24.5M |
| 自由现金流率自由现金流/营收 | 17.8% | -254.2% |
| 资本支出强度资本支出/营收 | 4.4% | 6.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-13.6M | $-55.0M |
8季度趋势，按日历期对齐
经营现金流PLXRCAT
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-3.7M | $-23.9M | ||
| Q2 25 | $-5.2M | — | ||
| Q1 25 | $-5.1M | $-15.9M | ||
| Q4 24 | $4.0M | $-10.1M | ||
| Q3 24 | $4.1M | — | ||
| Q2 24 | $-3.6M | — | ||
| Q1 24 | — | $-4.1M |
自由现金流PLXRCAT
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-4.2M | $-24.5M | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-5.4M | $-16.2M | ||
| Q4 24 | $3.6M | $-10.2M | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | — | ||
| Q1 24 | — | $-4.2M |
自由现金流率PLXRCAT
| Q4 25 | 17.8% | — | ||
| Q3 25 | -23.7% | -254.2% | ||
| Q2 25 | -36.2% | — | ||
| Q1 25 | -53.0% | -992.9% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | — | ||
| Q1 24 | — | -71.1% |
资本支出强度PLXRCAT
| Q4 25 | 4.4% | — | ||
| Q3 25 | 2.8% | 6.9% | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 3.0% | 16.8% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | — | 0.8% |
现金转化率PLXRCAT
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
RCAT
| Products | $8.5M | 88% |
| Services | $1.2M | 12% |
